MedTrace Logo

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

NCT04155515 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2021-02-04

No results posted yet for this study

Summary

A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients

Conditions

  • Chronic Hepatics C Virus (HCV) Genotype 1
  • Non-Cirrhotic
  • Cirrhosis
  • Treatment naïve

Interventions

DRUG

TG-2349

TG-2349 400mg

DRUG

DAG181

DAG181 200mg

DRUG

Ribavirin

Ribavirin 1000mg/1200mg

Sponsors & Collaborators

  • Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-13
Primary Completion
2020-08-11
Completion
2020-08-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155515 on ClinicalTrials.gov